Metformin vs GLP-1 for Weight Loss: Which Is Right for You?

Metformin vs GLP-1 for weight loss: which is better at a glance?

GLP-1–based medicines generally produce far more average weight loss than metformin, while metformin is far cheaper and can fit specific blood-sugar or metabolic goals. The table below shows the first, biggest difference. Your diagnosis, safety, cost, and ability to stay on treatment decide the practical choice from there.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred format (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

Is metformin or a GLP-1 better for weight loss?

For weight loss alone, an FDA-approved GLP-1–based medicine is usually the stronger choice — it produces far more average weight loss than metformin in clinical trials. Metformin can still be the more sensible first step when prediabetes, type 2 diabetes, PCOS, cost, or a preference for a cheap pill matter more than maximizing pounds lost. Efficacy alone doesn't decide it.

Let's be direct, because you came here for a straight answer.

If your only question is “which one takes off more weight?” — GLP-1–based medicines win, and it isn't close. In their trials, they took people from roughly 8% to over 20% of their starting body weight. Metformin, in the well-known Diabetes Prevention Program, averaged about 2 kg — a few pounds. That's a real gap.

But “better for weight loss” and “better for you” are not the same sentence. A medicine can win on the scale and still be the wrong call if you can't afford it, can't tolerate it, or can't stay on it. And metformin brings real strengths of its own: it's inexpensive, it has decades of clinical use, and it can directly support blood-sugar and metabolic goals when type 2 diabetes, high-risk prediabetes, or PCOS-related metabolic concerns are part of your picture. (GLP-1–based medicines can also treat type 2 diabetes — but under separate diabetes-brand labels with their own dosing and coverage rules.)

So the honest answer is this: the GLP-1 category is more powerful for weight loss, but the right choice depends on your diagnosis, your goal, your safety, your budget, and whether you can keep going long-term. The rest of this page helps you find your answer inside that.

One quick definition, because searches blur it: a GLP-1 receptor agonist is a class of medicine that mimics a gut hormone (glucagon-like peptide-1) to lower appetite and blood sugar. Semaglutide (Wegovy, Ozempic) is one. Tirzepatide (Zepbound, Mounjaro) is pharmacologically different — it's a dual GIP/GLP-1 receptor agonist, meaning it acts on two hormone pathways, not one. Consumer searches group it with GLP-1s, and that's fine as shorthand, but we'll keep the distinction clear where it changes the facts.

Should you try metformin before a GLP-1?

Not always. The right order depends on what's being treated, your medical history, how much weight you want to lose, your coverage, and your clinician's judgment. Sometimes starting with metformin makes sense; sometimes it doesn't. There is no universal “metformin first” rule for weight loss.

This comes up constantly, so let's settle it.

Trying metformin first can make sense if you have prediabetes, PCOS, or insulin resistance, if cost is a hard limit, or if you and your clinician want a lower-cost starting point. It's cheap, it's familiar, and starting it doesn't close any doors later.

But it is not a required first step. If your goal is a large amount of weight loss, metformin will likely fall short of it (more on that below), and forcing a “try the weak one first” step can just delay a treatment that fits you better. For some people the right move is to go straight to the GLP-1 conversation. Your clinician weighs your diagnosis, safety, and goals — not a one-size rule from the internet.

Metformin vs GLP-1 for weight loss: how do the numbers actually compare?

The cleanest way to compare these is to line up each medicine's trial result — but read them as an “order of magnitude,” not a leaderboard. Metformin's Diabetes Prevention Program result and the obesity-drug trials studied different people, ran for different lengths, and measured weight loss in different ways. The comparison is real, but it is not head-to-head.

Here's the evidence in one place. Read the caveat right below the table before you compare anything.

The RX Index evidence matrix: separate adult trial benchmarks (populations and methods differed)

* Foundayo's highest dose showed about 11% under the more conservative analysis and up to ~12.4% under the efficacy analysis. †Wegovy HD showed ~18.7% under the treatment-policy analysis (counts everyone, including those who stopped early) and ~20.7% under the efficacy analysis (STEP UP, Lancet Diabetes & Endocrinology, 2025).

Read this before you compare any of it:

These are not head-to-head results. Every obesity-medication row comes from a trial in which both the medicine group and the placebo group also got a reduced-calorie diet and more physical activity. The “Treatment-group average” column shows what the medicine group lost; the placebo column shows the comparison. It is not a placebo-adjusted, drug-only number. The metformin row comes from a separate diabetes-prevention trial in which the metformin and placebo groups got standard lifestyle advice rather than an intensive obesity-trial lifestyle program. Treat the table as context for scale — not as a race with a finish-line photo.

Three things the table quietly tells you:

1. The metformin row is a different kind of study. The Diabetes Prevention Program (DPP) wasn't a weight-loss registration trial — it was a diabetes-prevention study in adults at high risk (impaired glucose tolerance), and it ran for years. Metformin's job there was blood sugar; modest weight loss came along with it. In shorter, weight-focused trials, metformin's average tends to land in the low-to-mid single digits (roughly 3–7% of body weight), and a bit higher in some study groups — still well below the GLP-1 range.

2. A 15% average doesn't mean everyone loses 15%. Averages hide a huge range. In the Wegovy HD trial, about a third of people lost 25% or more of their body weight — while others lost much less. That's why the responder rate matters as much as the headline. Your result could land anywhere in that spread.

3. The top dose in a study isn't automatically your dose. These are the maximum doses tested. Your clinician decides what's right for you, and side effects often set the ceiling before the label does.

One thing we deliberately left out of this table: compounded drugs

You'll see “compounded semaglutide” and “compounded tirzepatide” advertised online, often much cheaper. We didn't put them in the results table, and here's the honest reason: compounded medicines are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before they're sold — so we can't present them as equivalent to the approved products above. Per current FDA guidance, a compounded product may be appropriate only when a licensed prescriber determines that a patient's medical needs cannot be met by an FDA-approved medicine. If you're weighing that option, it belongs in a conversation with a licensed clinician — not in an ad.

You've now seen the raw comparison. The next question is almost always: “Okay — but which of these fits me?” That depends on your diagnosis, your coverage, whether you want a pill or an injection, and your budget. Rather than guess, put your situation in and get a matched answer with real pricing — it takes about two minutes.

How does type 2 diabetes change your expected weight loss?

People with type 2 diabetes generally lose less weight on these medicines than people without diabetes — often several percentage points less. That makes your diabetes status one of the most important things to know before you set expectations, because the biggest headline numbers usually come from studies in people who don't have diabetes.

This is one of the most overlooked facts in the whole conversation, and knowing it up front can save you real disappointment.

The eye-popping figures above mostly come from trials in people without type 2 diabetes. When the same medicines are studied in people with type 2 diabetes, the average weight loss is meaningfully lower. Here's the side-by-side:

Why the difference? Honestly, researchers don't fully agree, and we won't pretend to. The trials show the averages differed — they don't establish one single cause. What we can say is that diabetes and the medicines used to treat it change the metabolic picture, and the American Diabetes Association's 2026 guidance says plainly: expect somewhat less weight loss from these drugs in people with diabetes, and set goals accordingly.

Here's the reframe that matters if this is you: the scale isn't the only win. Success in type 2 diabetes may include a lower A1C and — for products with the relevant evidence and FDA indication — heart or kidney benefits. A lighter medication load is possible in some treatment plans, though it's not guaranteed. Sometimes those wins matter more than the pounds.

If you've been diagnosed with prediabetes or diabetes, that changes which specific path fits, and we go deep on both in our Best GLP-1 for Prediabetes and Best GLP-1 for Diabetes guides. This page stays focused on the metformin-versus-GLP-1 decision itself.

How do metformin and GLP-1 medications work differently?

Metformin is a biguanide — it mainly lowers the sugar your liver makes and helps your body respond better to insulin. GLP-1–based medicines work on a different system: appetite, fullness, and how fast your stomach empties. Tirzepatide adds a second hormone pathway (GIP), so it's a dual GIP/GLP-1 medicine, not a pure GLP-1.

Understanding how they work explains why the weight-loss gap exists.

Metformin (a “biguanide” — an older class of diabetes pill) does its job mostly in your liver and muscles. It tells your liver to release less sugar and helps your cells use insulin. Some people also notice a little less appetite. But metformin is FDA-approved to improve blood-sugar control in type 2 diabetes; weight loss is a secondary observed effect, not its labeled purpose. That's a big reason its weight-loss effect is modest — it isn't primarily an appetite drug.

GLP-1 receptor agonists work where hunger lives. They mimic a natural gut hormone your body releases after eating, which:

• turns down appetite and food “noise”
• helps you feel full sooner and longer
• slows how fast your stomach empties
• helps your body release insulin when blood sugar is high

That directly affects appetite, fullness, energy intake, and gastric emptying — which helps explain the larger average weight changes seen in obesity trials.

Tirzepatide adds a second key. On top of the GLP-1 pathway, it also activates a hormone called GIP. In a head-to-head trial (SURMOUNT-5), tirzepatide produced more average weight loss than semaglutide. Just keep the label straight: it's a dual GIP/GLP-1 medicine, and calling it “just a GLP-1” isn't quite right.

Does knowing the mechanism tell you exactly how much you'll lose? No. Your body, your dose, your tolerance for side effects, whether you stay on it, and your diagnosis all matter more than the biology on paper.

How fast do metformin and GLP-1 medications work?

There's no universal timeline, and trial endpoints are not monthly forecasts. GLP-1 trials measured their headline weight loss at 56 to 72 weeks, with loss building gradually as the dose steps up over months. Metformin's main long-term study ran for years. Early weeks tell you about tolerance more than final results.

People want a week-by-week promise, and there isn't an honest one.

The big GLP-1 numbers you've seen are measured at the end of long trials — 68 weeks for Wegovy, 72 for Zepbound and Foundayo. The dose is raised slowly over the first months to limit side effects, so weight comes off gradually, not all at once. Many people see steady change over many months rather than a fast drop.

Metformin's headline benchmark comes from a study that averaged nearly three years. Weight change on metformin also builds slowly and stays modest.

The practical takeaway: judge these medicines over months, with your clinician, not by the first few weeks on the scale.

Who is metformin the better choice for?

Metformin may be the smarter first conversation when a clinician is managing type 2 diabetes, high-risk prediabetes, or PCOS-related insulin resistance, and you value a cheap, familiar pill. It's not FDA-approved for weight loss, and its average weight effect is modest compared with the GLP-1 drugs — but for the right person, “modest, affordable, and well-understood” beats “powerful and expensive.”

Metformin gets treated like the consolation prize. It isn't. For some people it's genuinely the right first move. Here's who.

If you have type 2 diabetes. Metformin is FDA-approved to improve blood-sugar control in type 2 diabetes and remains a common first option. Your starting regimen is individualized around blood sugar, heart, kidney, weight, safety, cost, and how many medicines you're already taking. If this is you, metformin isn't “settling” — it's often exactly where treatment begins.

If you have high-risk prediabetes. Lifestyle change is still the foundation, but metformin is sometimes added for selected high-risk adults to help prevent diabetes. (This is a prevention decision your clinician makes — prediabetes isn't an official FDA weight-loss use for metformin.)

If you have PCOS. The 2023 International PCOS Guideline says metformin should be considered in adults with PCOS and a BMI of at least 25 for anthropometric and metabolic outcomes — including insulin resistance, glucose, and lipids. It also says anti-obesity medicines such as liraglutide and semaglutide may be considered for higher weight under general-population guidance. So metformin is a legitimate, evidence-backed option to raise — just not the automatic answer for everyone with PCOS.

If cost and access are the deciding factor. Generic metformin is widely available and inexpensive. Walmart's current low-cost list, for example, shows $9 for specified 30-day metformin quantities and $24 for 90 days; formulation, quantity, pharmacy, location, and coupons all change the price. It's an oral pill you can fill in most places. If a GLP-1's price means you'd start it and then have to quit, a medicine you can actually sustain may serve you better. (Cheap doesn't mean clinically better — but “the plan you can stick to” counts for a lot.)

The one honest catch with metformin

We promised straight talk, so here it is — the single most important limitation, said plainly:

Metformin is not a high-powered weight-loss drug. If losing a large amount of weight is your main goal, metformin will probably underdeliver. Its strongest case is metabolic fit, affordability, and easy access — not maximum pounds lost.

That's the trade. We're not softening it into “it's not perfect.” We're telling you the evidence-supported average is modest — not pretending that average is a hard ceiling for every single person, because some people do better than the average.

But here's the hopeful part, and it's real: if metformin fits your diagnosis, medical history, and budget, it can be a low-cost, long-used starting point — and it doesn't prevent a clinician from later adding or changing treatment if that becomes right for you. If you already know you want bigger results than metformin typically gives, don't force it. The next section is for you.

Who is a GLP-1 the better choice for?

An FDA-approved GLP-1–based medicine may fit you if you meet a product's weight-management criteria, want more weight loss than metformin usually delivers, and can safely stay on treatment and afford it. Which specific drug is right depends on your medical history, the warnings on its label, whether you want a pill or injection, your coverage, and your plan for the long haul — not just which trial had the biggest number.

If you've read this far and thought “I need more than a few pounds,” a GLP-1 is likely the conversation you want. Here's how to think about fit.

Do you meet the criteria? Broadly, these medicines are labeled for adults with obesity, or adults with overweight plus a weight-related condition (like high blood pressure, high cholesterol, or type 2 diabetes). If you're in that range, you may well meet a product's BMI-based threshold — but a clinician still confirms the diagnosis, any qualifying condition, contraindications, and the product-specific indication. A number you calculate at home isn't the final yes; it's the reason to book the conversation.

Pill or injection? In 2026 you have real choices:

• Weekly injections: Wegovy (semaglutide), Wegovy HD (higher-dose semaglutide), and Zepbound (tirzepatide) — the most powerful options on average.
• Daily pills: Foundayo (orforglipron), FDA-approved in April 2026, and a semaglutide tablet (Wegovy). Pills can be more convenient; the top injections tend to produce more weight loss.

The oral pills are not taken the same way (this trips people up — see the next section).

Know the brand-versus-diabetes-brand difference. This confuses almost everyone:

• Wegovy contains semaglutide and is approved for chronic weight management. Ozempic also contains semaglutide but has different FDA-approved indications and dosing.
• Zepbound contains tirzepatide and is approved for chronic weight management. Mounjaro also contains tirzepatide but has different FDA-approved indications and dosing.

Ozempic and Mounjaro are not FDA-approved for weight loss, even though you hear their names everywhere. And branded medicines are not the same as compounded versions — don't let anyone blur the two.

The one honest catch with GLP-1s

Same deal as metformin — the most important limitation, said plainly:

GLP-1 medicines are not a short-term fix. They cost more, they commonly cause stomach side effects, coverage can change, each drug carries its own risks, and — this is the big one — stopping usually leads to substantial average weight regain. For many people, this is ongoing treatment, not a 12-week cleanse.

We cover the “what happens if you stop” question in full below, because it's the objection that stops people cold — and it deserves a real answer, not a dodge.

Here's the part that should give you confidence: none of that means a GLP-1 is a bad idea. It means it's a decision you make with your eyes open — with a plan for cost, tolerance, and staying on it. That limitation doesn't erase the results in the trials above. It means you go in with a realistic plan for cost, side effects, continued access, and maintenance. If that's the path you're leaning toward, the fastest way to find the right provider for your state, coverage, and format is to match your situation:

Which oral option is easier to take: Foundayo or Wegovy tablets?

They are not interchangeable in how you take them. Foundayo (orforglipron) is taken once daily with or without food, any time of day. The semaglutide tablet (Wegovy) is taken in the morning on an empty stomach with no more than 4 ounces of water, then you wait at least 30 minutes before any food, drink, or other pill. Oral format alone doesn't decide effectiveness or convenience for you.

If you want a pill instead of an injection, this practical difference matters more than most people expect.

Foundayo is the flexible one: any time of day, with or without food or water restrictions. For a lot of people, that's easier to fit into real life.

The semaglutide tablet (Wegovy) has strict timing: first thing in the morning, empty stomach, only a small sip of water (up to 4 ounces), and then a 30-minute wait before you eat, drink, or take anything else. Miss the routine and it may not work as intended.

Neither one is “better” on convenience for everyone — it depends on your mornings and your habits. On average, the top injections still produce more weight loss than either pill. Effectiveness, tolerance, cost, and how well the routine fits your day all go into the choice.

What are the side effects and serious risks of metformin vs GLP-1?

Both metformin and GLP-1 medicines commonly cause stomach and gut side effects, but their serious risks differ. Metformin's key concerns are kidney function, a rare condition called lactic acidosis, and vitamin B12 levels. Each GLP-1 medicine carries its own warnings — including a thyroid-tumor boxed warning — so the specifics should come from that drug's current label, not a generic list.

Nobody should choose a medicine without knowing what it can do to them. Here's the honest safety picture.

Metformin side effects and precautions

Common (usually mild, often fade with time): diarrhea, nausea or upset stomach, gas, and belly discomfort. Starting low and going slow usually helps — but dosing is your prescriber's call, not something to DIY from an article.

Serious or worth monitoring:

• Kidney function. Metformin is not recommended to start if your kidney function (eGFR) is between 30 and 45, and it's not to be used below 30. Your clinician checks this.
• Lactic acidosis. A rare but serious buildup of acid in the blood — it carries a boxed warning. Certain situations (severe illness, dehydration, some imaging dyes) raise the risk.
• Vitamin B12. The current metformin extended-release label recommends checking blood counts yearly and vitamin B12 every two to three years, since long-term use can lower B12.

Never stop a medication on your own based on something you read here — including this page. Bring the concern to your clinician.

GLP-1 side effects and precautions

Common (this is the big one — and often the reason people stop): nausea, vomiting, diarrhea, constipation, and belly pain. These are usually worst when you start or step up a dose, and they tend to settle. But for some people they're a dealbreaker, and that's valid.

Serious warnings — take the specifics from each drug's label:

If you're pregnant or planning to be — read this box

Do not use weight-loss medication during pregnancy. If you're trying to conceive or breastfeeding, follow the current label for the specific product and a clinician-directed plan — because washout timing, contraception, and breastfeeding instructions differ by medicine. For example, some products advise a backup or non-oral contraceptive method for several weeks after you start and after each dose increase, because the medicine can affect how well the pill absorbs. (Metformin is sometimes used in other pregnancy-related situations, but that does not make it a pregnancy weight-loss drug.) This is a conversation to have before anything else.

We're not putting a “book now” button under a safety section. Read it, sit with it, and take your questions to a professional.

Can you take metformin and a GLP-1 together?

Yes — metformin and a GLP-1–based medicine are sometimes prescribed together, especially in type 2 diabetes care, and many GLP-1 trials included people already taking metformin. But that doesn't mean everyone should combine them, and it does not mean their weight-loss effects simply add up. A clinician weighs your blood sugar, gut tolerance, kidney function, and other medications first.

This is a common and reasonable question, and the answer is refreshingly practical.

Why a clinician might use both: they work through different systems, so a clinician may add a GLP-1–based medicine to metformin when it fits your blood-sugar, weight, heart, kidney, safety, and treatment-load goals. If you're already on metformin and need more, adding a GLP-1 is one option they may consider.

What combining them does not prove:

• It does not guarantee more weight loss than a GLP-1 alone.
• You cannot add the two trials' numbers together (metformin's few percent + a GLP-1's 15% ≠ some bigger total).
• Both medicines can cause gastrointestinal side effects, so combined tolerability needs clinician review.

Questions to bring to your prescriber if you're considering both: What is each medicine treating in my case? Which result tells us it's working — the scale, my A1C, or both? Which side effects mean I should call you? Does anything else I take need adjusting? How will you monitor my kidney function and B12?

Which costs less: metformin or a GLP-1?

Metformin is dramatically cheaper — often under $15 a month as a generic. FDA-approved GLP-1 medicines commonly run from roughly $150 to $700 a month through manufacturer cash-pay programs, and more without any program. Your real GLP-1 cost depends on the exact drug, your dose, insurance, program terms, refill timing, and any telehealth membership — so check the current price for your dose.

Cost is often the quiet dealbreaker, so let's be concrete — and let's actually show the prices, not send you off to hunt for them.

Generic metformin

About as cheap as prescriptions get. Walmart's current low-cost list shows $9 for specified 30-day metformin quantities and $24 for 90 days. Exact price depends on the pharmacy, quantity, immediate- vs. extended-release, and any coupon. (Retail example verified July 14, 2026.)

FDA-approved GLP-1 cash prices by dose

List prices and cash-pay prices differ sharply by product, dose, format, insurance, and manufacturer program. Here are the current manufacturer cash-pay pathways rather than one class-wide “$1,000+” number:

Prices, offers, and refill terms change — confirm the current number for your exact dose on the manufacturer's page before you commit. Eligible commercially insured patients may pay far less (for example, as little as $25/month for Foundayo with a savings card, subject to terms), and eligible Medicare Part D members may access Foundayo for $50/month through the Medicare GLP-1 Bridge program (which requires meeting clinical criteria — it's not a guarantee of coverage).

Membership vs. medication — don't confuse them

Telehealth companies often charge a membership separate from the medication. Ro is a transparent example: Ro Body membership is $39 for the first month, then $149/month, or as low as $74/month with the annual plan paid upfront — and the medication is billed separately. So a “starting at $39” headline is the membership, not the drug. Always ask what's included. (Ro pricing verified July 14, 2026.)

Insurance and prior authorization

There's no universal “insurance covers GLP-1s” answer. Coverage depends on your specific plan, diagnosis, the exact product, the formulary, and prior-authorization rules — and a diabetes-brand rule doesn't automatically apply to an obesity brand. It's worth checking your own plan, and some providers (like Ro) will start the prior-authorization paperwork for you. For the full cash-pay picture, see our GLP-1 cost without insurance guide.

Now that you can see the real costs, the decision usually gets a lot clearer. To pin down the exact price and likely coverage steps for your situation:

What happens if you stop metformin or a GLP-1?

Studies show that stopping semaglutide or tirzepatide leads to substantial average weight regain — not all of it, and not the same for everyone, but a real amount on average. Metformin doesn't have the same long-term weight-regain research, so don't assume the same pattern. Either way, the smart move is to plan for maintenance, cost, and monitoring before you start.

This is the objection that stops people, so we're going to answer it honestly instead of pretending it away.

After stopping tirzepatide: In the SURMOUNT-4 trial, people who came off tirzepatide (switched to placebo) regained a mean of 14.0% of their body weight over the following year, while those who kept taking it lost an additional ~5.5% on average. The direction is consistent: stop, and much of the loss reverses for many people.

After stopping semaglutide: In a well-known follow-up to the STEP 1 trial, people who came off semaglutide (and the lifestyle support) regained a large share of their lost weight over the next year, and several health improvements drifted back toward baseline. Not everyone regained everything — but the average trend was clear.

After stopping metformin: Here we won't overclaim. There isn't the same body of weight-regain research, and what happens depends on why you were taking it and what else changes in your life. Ask your clinician whether your blood sugar, appetite, or weight should be watched afterward.

The takeaway isn't “don't start.” It's plan before you start. Ask yourself: Can I afford this beyond the introductory period? What's my clinician's maintenance plan? What would make us continue, change, or stop it? What support do I have if my coverage ends?

Weight regain after stopping is a real limitation of GLP-1 treatment. A plan can't guarantee you'll keep it all off — but it lets you decide how you'll maintain, monitor, and afford treatment before you begin, instead of being caught off guard. That's exactly why we point people to a tool that helps build that plan, instead of handing you a link and wishing you luck.

Is metformin or a GLP-1 better for PCOS, prediabetes, or insulin resistance?

It depends on the goal. For PCOS, metformin may be considered for metabolic and weight-related outcomes, while GLP-1 medicines may also be considered for higher weight under general obesity guidance. Prediabetes, diabetes, pregnancy plans, and how much weight you want to lose all change the answer — so neither one is universally “best for PCOS” or “best for insulin resistance.”

This is where a lot of readers actually live, so let's take each one.

PCOS

The 2023 International PCOS Guideline supports two ideas at once: metformin should be considered in adults with PCOS and a BMI of at least 25 for metabolic and body-measurement outcomes (including insulin resistance, glucose, and lipids), and anti-obesity medicines such as liraglutide and semaglutide may be considered for higher weight under general-population guidance. Which fits depends on whether your priority is metabolic and cycle-related benefits or larger weight loss — and on your own numbers and history.

Two must-know cautions if you have PCOS and any chance of pregnancy: GLP-1 weight-loss medicines aren't for use while pregnant or trying to conceive, so a clinician-directed contraception and timing plan matters — and these can be long-term treatments with weight regain after stopping. We're flagging that plainly because PCOS content online too often uses fertility hope as a sales lever. We won't.

Prediabetes

Lifestyle change is still the center of the plan. Metformin may be considered for selected high-risk adults to help prevent diabetes. Separately, you might independently qualify for a GLP-1 based on your weight. If prediabetes is your situation, our Best GLP-1 for Prediabetes guide covers the GLP-1-specific path in detail.

“Insulin resistance”

An honest note: the phrase gets used loosely online, and a lot of people describe themselves as “insulin resistant” without a formal diagnosis. That's not a knock — it's just a reason to be careful. What matters is what your clinician is actually measuring (labs, history, symptoms). Metformin directly targets insulin resistance, which is part of its appeal here. But neither medicine “cures” insulin resistance permanently, and self-diagnosis shouldn't drive the choice.

Type 2 diabetes

When diabetes is in the picture, the decision widens beyond weight to blood sugar, heart and kidney protection, and how many medicines you're on. Metformin is often the starting point; a GLP-1 may be added or chosen for its combined blood-sugar and weight benefits. Our Best GLP-1 for Diabetes guide goes deep there.

How should you decide what to ask your clinician?

Organize the decision around six things: your diagnosis, how much weight you want to lose, your safety profile, a cost you can sustain, whether you prefer a pill or injection, and your plan for staying on treatment. Sort those out, and the “metformin vs GLP-1” question usually answers itself — or narrows to a short, specific conversation with your clinician.

You don't need to walk into an appointment with the answer. You need the right questions.

The eight questions worth asking: What condition would each medicine be treating in my case? What's a realistic result for someone with my diagnosis? Do I meet the criteria for an FDA-approved weight-loss medicine? Does my kidney function or medical history change either option? If pregnancy is possible, how does that affect timing? What will this actually cost after any introductory pricing? What happens if I can't tolerate it or can't keep paying? Could both ever make sense, and what would each one add?

What to bring with you: your current medication list, any relevant diagnoses, recent A1C or blood-sugar results if you have them, kidney-function info if available, your insurance formulary or any denial letter, your monthly budget, whether pregnancy is a possibility, and any past medication side effects.

The Find My GLP-1 Path tool turns those six factors into a personalized discussion plan and a matched next step — it won't diagnose you or hand you a prescription, but it'll make sure you don't walk in unprepared.

What readers keep telling us

We're not going to show you a wall of glowing before-and-after stories. On a two-medicine comparison, testimonials can't prove which drug is safer or more effective, and a highlight reel of success stories would quietly push you toward the more expensive option.

Here's the concern that comes up again and again, in plain terms: readers tell us they're doing the work — eating well, moving more — and the scale has stalled. That plateau is real, and it's often what sends people looking for a medication in the first place. (If that's you mid-treatment, our GLP-1 plateau guide covers why it happens and what actually helps.)

If you're there, you're not doing it wrong, and you're not out of options. You may just be at the point where a medication conversation is reasonable.

Our methodology: what did The RX Index actually verify?

We checked FDA approval status and pivotal trial results against primary and authoritative sources, used the Diabetes Prevention Program and current clinical guidelines for metformin and diagnosis context, and dated our pricing. We did not treat separate trials as head-to-head, use patient stories as proof of results, or let any affiliate relationship decide the medical conclusion.

Independence only means something if we show our work.

What we verified (July 14, 2026):

• Metformin's FDA-approved use (blood-sugar control in type 2 diabetes) and that it's not approved for weight loss
• Metformin's average weight result in the Diabetes Prevention Program
• Trial results for Saxenda (SCALE), Wegovy (STEP 1), Wegovy HD 7.2 mg (STEP UP), Zepbound (SURMOUNT-1), and Foundayo/orforglipron (ATTAIN-1), plus the FDA approvals of Wegovy HD (March 2026) and Foundayo (April 2026)
• The head-to-head SURMOUNT-5 result (tirzepatide vs semaglutide) and the SURMOUNT-4 withdrawal result
• That weight loss is generally lower in people with type 2 diabetes, per the ADA's 2026 guidance
• Metformin's kidney, lactic-acidosis, and B12 label information
• PCOS guidance from the 2023 International PCOS Guideline
• Generic metformin pricing, current manufacturer cash-pay prices, and Ro's membership pricing

What we did NOT claim (because it can't be verified, or shouldn't be):

• Your individual eligibility or exact expected weight loss
• Your specific insurance coverage
• That prices won't change — cash-pay offers and refill terms move, so confirm current
• That compounded products are equivalent to FDA-approved ones
• A single “best” medicine for everyone
• Any firsthand use of either medicine by our team
• That any reader's experience represents a typical result

How we rank our sources: current FDA prescribing information first, then original clinical trials, then current clinical guidelines, then official manufacturer pricing, then retailer pricing, then our own editorial interpretation of those facts. Forums are used only for reader language — never for medical claims.

Corrections and updates: if you spot something out of date, tell us and we'll fix it. We update the “Last verified” date only after actually rechecking the facts.

Who made this and why: the RX Index editorial team built this page to help you prepare for an informed conversation with a clinician. Affiliate relationships are disclosed and don't change the factual claims, the trial results we cite, or how we built the evidence tables. We don't invent reviewers, credentials, or first-person stories. Read more in our editorial standards.

What else should you know about metformin vs GLP-1 for weight loss?

The remaining questions are about sequencing, combination treatment, oral options, cost, and what happens after stopping. These answers are short by design; each links back to the fuller sections above.

Still deciding? Let's make it simple.

You came here to answer one question: metformin, or a GLP-1? Here's the short version one more time. If your goal is metabolic health or modest weight loss on a tight budget, metformin is a real, legitimate, low-cost first conversation. If you want substantially more weight loss and can plan for the cost and the long haul, an FDA-approved GLP-1 is the stronger path. Your diagnosis, safety, and coverage decide the rest.

You don't have to figure that out alone.

Sources

• Diabetes Prevention Program (metformin weight and diabetes-prevention outcomes). DPP Research Group, New England Journal of Medicine, 2002. Link
• SCALE Obesity and Prediabetes (liraglutide 3 mg / Saxenda). Pi-Sunyer X, et al. New England Journal of Medicine, 2015. Link
• STEP 1 (semaglutide 2.4 mg). Wilding JPH, et al. New England Journal of Medicine, 2021. Link
• STEP UP (semaglutide 7.2 mg / Wegovy HD). The Lancet Diabetes & Endocrinology, 2025; Novo Nordisk topline release, January 2025; FDA approval of Wegovy HD, March 2026. Link
• SURMOUNT-1 (tirzepatide 15 mg). Jastreboff AM, et al. New England Journal of Medicine, 2022. Link
• SURMOUNT-4 (tirzepatide withdrawal). Aronne LJ, et al. JAMA, 2023. Link
• SURMOUNT-5 (tirzepatide vs semaglutide, head-to-head). New England Journal of Medicine, 2025. Link
• ATTAIN-1 and FDA approval of Foundayo (orforglipron). Eli Lilly and FDA, April 1, 2026.
• STEP 2 (semaglutide in type 2 diabetes) and SURMOUNT-2 (tirzepatide in type 2 diabetes).
• American Diabetes Association, Standards of Care in Diabetes — 2026. Link
• 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS (Monash University). Link
• Metformin prescribing information (FDA / DailyMed): indications, renal (eGFR) limits, boxed warning for lactic acidosis, vitamin B12. Link
• Current FDA prescribing information for Wegovy, Zepbound, Saxenda, and Foundayo (side effects, boxed warnings, pregnancy, contraception, administration).
• FDA statement on unapproved and compounded GLP-1 drugs used for weight loss. Link
• Manufacturer and retailer pricing: Novo Nordisk / NovoCare for Wegovy; Eli Lilly / LillyDirect for Zepbound and Foundayo; Walmart for the metformin retail example; Ro for membership and provider pricing (verified July 14, 2026).

Last verified: July 14, 2026. Pricing, FDA status, and provider policies change — we re-verify on a monthly-to-quarterly cadence and update the date only after rechecking.